Manne Upender, Srivastava Rashmi-Gopal, Srivastava Sudhir
Department of Pathology, University of Alabama, USA.
Drug Discov Today. 2005 Jul 15;10(14):965-76. doi: 10.1016/S1359-6446(05)03487-2.
With the availability of new technologies and the increased interest of medical practitioners to use molecular biomarkers in early detection and diagnosis, and in the prediction of therapeutic treatment efficacy and clinical outcomes, the academic and research institutions, as well as the pharmaceutical industry, have increased their efforts to develop novel molecular biomarkers for several human diseases, including cancer. The identification of molecular biomarkers also enables the development of a new generation of diagnostic products and to integrate diagnostics and therapeutics. This integrated approach will aid in 'individualizing' the medical practice. Here, we address issues related to the development of biomarkers, novel technological platforms used for drug development, future technologies and strategies for validating biomarkers for their clinical utility.
随着新技术的出现以及医学从业者对利用分子生物标志物进行早期检测、诊断、预测治疗效果和临床结果的兴趣增加，学术和研究机构以及制药行业都加大了力度，为包括癌症在内的多种人类疾病开发新型分子生物标志物。分子生物标志物的识别还推动了新一代诊断产品的开发，并实现了诊断与治疗的整合。这种整合方法将有助于实现医疗实践的“个性化”。在此，我们讨论与生物标志物开发、用于药物开发的新型技术平台、验证生物标志物临床效用的未来技术和策略相关的问题。
